Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers

Grace Kong; Geertje Noe; Cherie Chiang; Ken Herrmann; Thomas A Hope; Michael Michael

doi:10.1111/jne.13461

Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers

J Neuroendocrinol. 2024 Nov 9:e13461. doi: 10.1111/jne.13461. Online ahead of print.

Authors

Grace Kong^{1

2}, Geertje Noe³, Cherie Chiang^{4

5}, Ken Herrmann⁶, Thomas A Hope^{7

8}, Michael Michael^{2

9}

Affiliations

¹ Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
³ Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Department of Internal Medicine, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
⁵ Department of Diabetes and Endocrinology, Melbourne Health, University of Melbourne, Parkville, Victoria, Australia.
⁶ Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
⁷ Department of Radiology, San Francisco VA Medical Center, San Francisco, California, USA.
⁸ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
⁹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

PMID: 39520276
DOI: 10.1111/jne.13461

Abstract

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN). Its use is anticipated to increase significantly, and this demands accurate tools and paradigms to assess treatment response post PRRT. This article outlines the current role and future developments of anatomical, molecular imaging and biomarkers for response assessment to PRRT, highlighting the challenges and provides perspectives for the need to focus on a multimodality, multidisciplinary and individualised approach for patients with this complex heterogeneous disease.

Keywords: PRRT; biomarkers; molecular imaging; radiology; response.

Publication types

Review